The Bipolar Journey exhibit's consumer-focused activities provide insight and clarity into the life of a patient living with and managing bipolar depression
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression
will receive either RG2417 or a placebo twice a day for eight weeks.
AstraZeneca will be the first company to bring an atypical antipsychotic to the bipolar depression
market as a monotherapy, following demonstration of efficacy with quetiapine.
The results "provide a starting point for further studies on processing of rewarding stimuli in patients with unipolar and bipolar depression
The new report entitled Bipolar Depression
: Despite Negative Results, Physicians Still Hopeful About Aripiprazole also finds that an oral therapy that carries a lower risk of weight gain than Seroquel would earn a 21 percent patient share in bipolar depression
in the United States and a 30 percent patient share in Europe, according to surveyed U.
This survey clearly demonstrates that many people with bipolar disorder are feeling the effects of bipolar depression
in their day-to-day lives," said Linda Rosenberg, president and CEO of the National Council for Community Behavioral Healthcare.
Symbyax was the first drug approved by the FDA for acute treatment of bipolar depression
in adults in 2003.
Though not approved for this indication, lamotrigine had been considered by many clinicians to be one of "the big four" options for treating bipolar depression
, largely because of its good tolerability.
There is a desperate need for an effective treatment for bipolar depression
, a devastating condition which often leads patients to take their own lives," said Terence A.
said "We are delighted by the thorough analysis and sober conclusions of the APA task force in recognizing that D-cycloserine may play a critical role in addressing the major unmet need in bipolar depression
treatment, including the high risk of suicidal behavior.
LFMS is a first-in-class, non-invasive neuromodulation technology that has demonstrated a unique, rapid-acting effect in major depressive disorder and bipolar depression
In a previously published study of 318 patients randomized to either lurasidone dosage groups or placebo, the drug's association at both dose ranges with reduced Montgomery-Asberg Depression Scale total scores and Clinical Global Impressions scale for bipolar depression
severity scores from baseline to week 6 was significant.